Clinical Trials
Inovio Reports New Positive Clinical Data on Vaccine Advances in the Fight Against Emerging Infectious Diseases
Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)’s 1st Scientific Meeting on “Vaccines Against...
Clinical Trials
Delmar Pharmaceuticals announces dosing of first patient in Phase two clinical trial of VAL-083
DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Announced that patient dosing has commenced in a Phase 2 clinical study of its investigational drug VAL-083 (dianhydrogalactitol) for...
Clinical Trials
Aslan pharmaceuticals announces first patient enrolled in phase 1 study of Varlitinib in japan
ASLAN Pharmaceuticals , a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types announced that they are initiating enrolment of the first patient in the phase 1 clinical trial for varlitinib (ASLAN001)...
Clinical Trials
Envisia therapeutics releases interim Env515 phase 2 data results
Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology released an interim analysis of the second cohort of its ENV515 (travoprost XR) phase 2 trial in patients with glaucoma. ...
Clinical Trials
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial
Astellas Pharma Inc and Ironwood Pharmaceuticals Inc announced top-line results indicating that the Phase III clinical trial of linaclotide conducted in Japan in adults with chronic constipation (CC) met its primary endpoint. Linaclotide is approved in...
Clinical Trials
New UK primary care clinical trials company Interface Clinical Research to offer a more effective model
New clinical trials company, Interface Clinical Research, outlined a new model for running primary care clinical trials at their launch yesterday at the Royal Society in London. Interface will work in partnership with GP practices across...
Clinical Trials
Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
Pluristem Therapeutics Inc , a leading developer of placenta-based cell therapy products, today announced that it has completed enrollment of all 172 patients in a multinational Phase II trial of its PLX-PAD cells in the treatment of intermittent claudication (IC), a peripheral...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.